JP2021526509A5 - - Google Patents
Info
- Publication number
- JP2021526509A5 JP2021526509A5 JP2020564389A JP2020564389A JP2021526509A5 JP 2021526509 A5 JP2021526509 A5 JP 2021526509A5 JP 2020564389 A JP2020564389 A JP 2020564389A JP 2020564389 A JP2020564389 A JP 2020564389A JP 2021526509 A5 JP2021526509 A5 JP 2021526509A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- seq
- sequence shown
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023093016A JP7662707B2 (ja) | 2018-05-14 | 2023-06-06 | 抗ｃｄ２４組成物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671193P | 2018-05-14 | 2018-05-14 | |
| US62/671,193 | 2018-05-14 | ||
| PCT/US2019/031983 WO2019222082A1 (en) | 2018-05-14 | 2019-05-13 | Anti-cd24 compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093016A Division JP7662707B2 (ja) | 2018-05-14 | 2023-06-06 | 抗ｃｄ２４組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021526509A JP2021526509A (ja) | 2021-10-07 |
| JP2021526509A5 true JP2021526509A5 (https=) | 2022-05-19 |
| JP7294758B2 JP7294758B2 (ja) | 2023-06-20 |
Family
ID=68540727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564389A Active JP7294758B2 (ja) | 2018-05-14 | 2019-05-13 | 抗ｃｄ２４組成物及びその使用 |
| JP2023093016A Active JP7662707B2 (ja) | 2018-05-14 | 2023-06-06 | 抗ｃｄ２４組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093016A Active JP7662707B2 (ja) | 2018-05-14 | 2023-06-06 | 抗ｃｄ２４組成物及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US12286485B2 (https=) |
| EP (1) | EP3813877A4 (https=) |
| JP (2) | JP7294758B2 (https=) |
| KR (2) | KR102844265B1 (https=) |
| CN (2) | CN112424441B (https=) |
| AU (2) | AU2019269361C1 (https=) |
| BR (1) | BR112020022482A2 (https=) |
| CA (1) | CA3099554A1 (https=) |
| EA (1) | EA202092306A1 (https=) |
| IL (1) | IL278689B1 (https=) |
| MX (3) | MX2020012091A (https=) |
| SG (1) | SG11202010589YA (https=) |
| TW (1) | TWI835794B (https=) |
| WO (1) | WO2019222082A1 (https=) |
| ZA (1) | ZA202006647B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2020261280A1 (en) * | 2019-06-25 | 2020-12-30 | Ichilov Tech Ltd. | Anti-cd24 antibody and uses thereof |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| CN117412770A (zh) * | 2021-02-08 | 2024-01-16 | 德琪(杭州)生物有限公司 | 新颖抗cd24抗体 |
| WO2022178163A2 (en) * | 2021-02-18 | 2022-08-25 | Health Research, Inc. | Antibody-derived t cell activating technologies |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| US20250263499A1 (en) * | 2021-07-06 | 2025-08-21 | Shenghe (China) Biopharmaceutical Co., Ltd. | Anti-cd24 antibody and use thereof |
| EP4408862A4 (en) * | 2021-09-28 | 2025-11-12 | Acroimmune Guangzhou Biotech Ltd | Fusion proteins including the O71 core peptide and their use |
| CN113831412B (zh) * | 2021-10-13 | 2023-06-20 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向cd24的抗体及其制备和用途 |
| CN118369340A (zh) * | 2021-11-25 | 2024-07-19 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗原结合蛋白 |
| CA3240338A1 (en) * | 2021-12-07 | 2023-06-15 | Xiao Feng | Anti-cd24 antibody and use thereof |
| CN115947855B (zh) * | 2022-05-20 | 2023-10-27 | 杭州邦顺制药有限公司 | 抗cd24抗体的制备及其用途 |
| CN120380019A (zh) * | 2022-10-27 | 2025-07-25 | 北京星奇原生物科技有限公司 | 抗cd24抗体及其用途 |
| CN120112561A (zh) * | 2022-11-01 | 2025-06-06 | 南京昂科免疫生物医药有限公司 | 一种cd24结合蛋白及其用途 |
| CN115960243B (zh) * | 2023-01-09 | 2025-05-06 | 中国药科大学 | 靶向cd24和cd3的双特异性抗体及其应用 |
| EP4724496A1 (en) * | 2023-06-09 | 2026-04-15 | TJ Biopharma (Shanghai) Co., Ltd. | Anti-cd24 antibodies and uses thereof |
| WO2025075440A1 (ko) * | 2023-10-04 | 2025-04-10 | 재단법인대구경북과학기술원 | 항-cd24 항체 또는 이의 항원 결합 단편 및 이의 용도 |
| CN119823282A (zh) * | 2023-10-12 | 2025-04-15 | 江苏融泰生物技术有限公司 | 抗体融合蛋白及应用 |
| WO2025085805A1 (en) * | 2023-10-20 | 2025-04-24 | OncoC4, Inc. | Anti-cd24/anti-cd3 bispecific binding proteins and uses thereof |
| WO2025101970A1 (en) * | 2023-11-08 | 2025-05-15 | Pheast Therapeutics, Inc. | Cd24 antibodies |
| WO2025151423A1 (en) * | 2024-01-08 | 2025-07-17 | OncoC4, Inc. | Anti-cd24 antibody drug conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| CN1894413A (zh) | 2003-03-26 | 2007-01-10 | 特鲁比昂药品公司 | 识别cd3或4－1bb的抗体或基因介导的肿瘤反应性淋巴细胞活化 |
| WO2009063461A1 (en) * | 2007-11-14 | 2009-05-22 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating cancer using anti cd24 antibodies |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| US8808697B2 (en) * | 2010-04-28 | 2014-08-19 | Oncoimmune, Inc. | Methods of use of soluble CD24 for therapy of rheumatoid arthritis |
| EP2574627A1 (en) * | 2011-09-30 | 2013-04-03 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Particular uses of CD24 inhibitors |
| US9562110B2 (en) * | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| CA2926853C (en) | 2013-10-18 | 2022-04-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
| CN103819561A (zh) * | 2014-01-22 | 2014-05-28 | 中国药科大学 | 抗cd24单克隆抗体、其可变区序列及其应用 |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| US9804170B2 (en) * | 2015-02-09 | 2017-10-31 | Bristol-Myers Squibb Company | Antibodies to polyethylene glycol |
| MA55746A (fr) | 2016-01-21 | 2022-03-02 | Novartis Ag | Molécules multispécifiques ciblant cll-1 |
-
2019
- 2019-05-13 AU AU2019269361A patent/AU2019269361C1/en active Active
- 2019-05-13 MX MX2020012091A patent/MX2020012091A/es unknown
- 2019-05-13 US US17/055,248 patent/US12286485B2/en active Active
- 2019-05-13 JP JP2020564389A patent/JP7294758B2/ja active Active
- 2019-05-13 WO PCT/US2019/031983 patent/WO2019222082A1/en not_active Ceased
- 2019-05-13 KR KR1020207033131A patent/KR102844265B1/ko active Active
- 2019-05-13 SG SG11202010589YA patent/SG11202010589YA/en unknown
- 2019-05-13 CA CA3099554A patent/CA3099554A1/en active Pending
- 2019-05-13 KR KR1020257026199A patent/KR20250122537A/ko active Pending
- 2019-05-13 BR BR112020022482-0A patent/BR112020022482A2/pt active IP Right Grant
- 2019-05-13 EA EA202092306A patent/EA202092306A1/ru unknown
- 2019-05-13 CN CN201980032893.9A patent/CN112424441B/zh active Active
- 2019-05-13 EP EP19803135.3A patent/EP3813877A4/en active Pending
- 2019-05-13 CN CN202310460291.1A patent/CN116589582A/zh active Pending
- 2019-05-13 TW TW108116423A patent/TWI835794B/zh active
-
2020
- 2020-10-26 ZA ZA2020/06647A patent/ZA202006647B/en unknown
- 2020-11-11 MX MX2025002661A patent/MX2025002661A/es unknown
- 2020-11-11 MX MX2024015039A patent/MX2024015039A/es unknown
- 2020-11-12 IL IL278689A patent/IL278689B1/en unknown
-
2023
- 2023-06-06 JP JP2023093016A patent/JP7662707B2/ja active Active
-
2025
- 2025-03-14 AU AU2025201864A patent/AU2025201864A1/en active Pending
- 2025-04-03 US US19/169,932 patent/US20250243292A1/en active Pending
- 2025-04-03 US US19/169,938 patent/US20250333532A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526509A5 (https=) | ||
| CN112955471B (zh) | Cd3抗体及其药物用途 | |
| CN110511278B (zh) | 抗b7-h6抗体、融合蛋白及其使用方法 | |
| DK1976880T3 (en) | Pharmaceutical compositions with resistance to soluble cea | |
| CN104955845B (zh) | 间皮素抗体和引起有效的抗肿瘤活性的方法 | |
| CN116261590B (zh) | 抗cd3抗体以及其用途 | |
| US20240197931A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
| CN118987201A (zh) | 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合 | |
| JP2021510736A5 (https=) | ||
| US20210040213A1 (en) | Immunomonotherapy for urothelial carcinoma | |
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| JP2025148435A (ja) | ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１ | |
| JP2025016452A (ja) | 癌の治療における放射免疫療法と免疫チェックポイント療法との組み合わせ | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| Caracciolo et al. | Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia | |
| JP2022523360A5 (https=) | ||
| JP2025510642A5 (https=) | ||
| MXPA06008942A (es) | Inmunoglobulinas anti-moleculas de adhesion a celulas epiteliales(epcam). | |
| JP2019535753A (ja) | 抗ＣＤ３００ｆ抗体およびその利用 | |
| KR20230028386A (ko) | 인간 질환의 치료를 위한 cd38 항체 | |
| CA3099974A1 (en) | Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof | |
| Clark et al. | Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment | |
| Garambois et al. | Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers | |
| CN118557748A (zh) | 使用抗cd123免疫缀合物的治疗方法 | |
| TW202005983A (zh) | 抗-人類pd-l1之抗體及其用途 |